UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Atrioventricular node ablation is an effective management strategy for atrial fibrillation in patients with hypertrophic cardiomyopathy

Butcher, Charles; Rajappan, Saffron; Wharmby, Amy L; Ullah, Waqas; Wong, Tom; Jones, David; Rajappan, Kim; ... Honarbakhsh, Shohreh; + view all (2023) Atrioventricular node ablation is an effective management strategy for atrial fibrillation in patients with hypertrophic cardiomyopathy. Heart Rhythm 10.1016/j.hrthm.2023.08.028. (In press).

[thumbnail of Lambiase_Atrioventricular node ablation is an effective management strategy for atrial fibrillation in patients with hypertrophic cardiomyopathy_AAM.pdf] Text
Lambiase_Atrioventricular node ablation is an effective management strategy for atrial fibrillation in patients with hypertrophic cardiomyopathy_AAM.pdf
Access restricted to UCL open access staff until 25 August 2024.

Download (507kB)

Abstract

BACKGROUND: Atrial fibrillation (AF) is common in hypertrophic cardiomyopathy (HCM) patients and can be challenging to manage. Atrioventricular node (AVN) ablation may be an effective management strategy for AF in these patients. OBJECTIVE: Assess the efficacy of AVN ablation in HCM patients who have failed medical therapy and/or catheter ablation for AF. METHODS: Multi-centre study with retrospective analysis of a prospectively collated HCM registry. AVN ablation patients were identified. Baseline characteristics, device and procedural indication were collected. Symptoms defined by NYHA and EHRA classification and echocardiographic findings during follow-up were assessed. RESULTS: Fifty-nine patients were included. Indications for AVN ablation were: 6 (10.2%) inappropriate ICD shock, 35 (59.3%) ineffective rate control and 18 (30.5%) to regularize rhythm to improve symptoms. During post-AVN ablation follow-up of (79.4±61.1 months), left ventricular ejection fraction (LVEF) remained stable (pre-LVEF 48.9±12.4%, post-LVEF 49.8±10.9%, p=0.68) even in those without a CRT device (pre-LVEF 54.3±8.0% vs post-LVEF 53.8±8.0%=0.65). Forty-nine (83.1%) patients reported an improvement in symptoms regardless of AF type (17/21, 81.0% paroxysmal vs. 32/38, 84.2% persistent AF; p=1.00), presence of baseline LV impairment (22/26, 84.6% LVEF≤50% vs. 27/33, 81.8% LVEF≥50%; p=1.00) or CRT device (27/32, 84.4% CRT vs. 22/27, 81.5% no CRT; p=1.0). Symptoms improved in 16 (89%) patients who underwent AVN ablation to regularize rhythm. CONCLUSION: AVN ablation improved symptoms without impacting LV function in a majority of the patients. AVN ablation is suggestive to be an effective and safe management approach for AF in HCM and should be further evaluated in larger prospective studies.

Type: Article
Title: Atrioventricular node ablation is an effective management strategy for atrial fibrillation in patients with hypertrophic cardiomyopathy
Location: United States
DOI: 10.1016/j.hrthm.2023.08.028
Publisher version: https://doi.org/10.1016/j.hrthm.2023.08.028
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions.
Keywords: Atrial Fibrillation, Atrioventricular node ablation, Hypertrophic Cardiomyopathy, Pace and Ablate
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science > Clinical Science
URI: https://discovery.ucl.ac.uk/id/eprint/10178946
Downloads since deposit
1Download
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item